Home › NDC Lookup › Ingredients › Emtricitabine And Tenofovir Disoproxil F... › 60687-0719-25
⚪no package photo
in the FDA label

Emtricitabine and tenofovir disoproxil fumarate 200; 300 mg; mg Tablet, Film Coated

by American Health Packaging · 30 BLISTER PACK in 1 CARTON (60687-719-25) / 1 TABLET, FILM COATED in 1 BLISTER PACK (60687-719-95)
NDC 60687-0719-25
🏷️ FDA NDC (as labeled) 60687-719-25 billing pads the product segment with a zero
Rx only Generic Discontinued Non-controlled ⚠ Discontinued by firm
🗂️ Data synced Mar 13, 2024 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Excluded from the active FDA NDC Directory. The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Mar 2026. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory. Search the FDA NDC Directory ↗

🆔 Identity & classification

FDA NDC (as labeled) 60687-719-25
Product NDC 60687-719
11-digit billing NDC 60687071925
NCPDP billing unit EA — each (per item)
Application # ANDA212689
Established class (EPC) Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleosi
DEA schedule Non-controlled
Marketing category ANDA
Marketing status Discontinued
FDA listing status Discontinued by firm (certified through Mar 2026)
Route ORAL
Dosage form TABLET, FILM COATED
Substance EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
GCN Seq No 057883
GCN 23152
HICL code 026515
Ingredient (HICL) Emtricitabine/Tenofovir (Tdf)
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W5
Therapeutic class — intermediate (HIC2) Antiviral Agents
HIC3 code W5O
Therapeutic class — specific (HIC3) Antivirals, Hiv-Spec, Nucleoside-Nucleotide Analog
AHFS code 08:18.08.20
AHFS class Hiv Nucleoside, Nucleotide Rt Inhibitors
FDB label name EMTRICITABINE-TENOFV 200-300MG
FDB brand name Emtricitabine-Tenofovir Disop
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 60687-719-25 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 60687-0719-25. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏭 Manufacturer & labeler

LabelerAmerican Health Packaging
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA212689 (ANDA)
Labeler code60687
Product typeHuman Prescription Drug
Portfolio673 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name EMTRICITABINE-TENOFV 200-300MG Ingredient Emtricitabine/Tenofovir (Tdf)
📖 What it is MedlinePlus · NLM

The combination of emtricitabine and tenofovir DF is used to treat HIV. Emtricitabine and tenofovir DF is also used along with practicing safer sex (e.g., condom use) to reduce the risk of HIV infection. Emtricitabine and tenofovir DF are in a class of medications called nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs). They work by slowing the spread of HIV in the body. Although emtricitabine and tenofovir DF will not cure HIV, these medications may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses. Taking these medication...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • If you already have HIV-1, this medication is part of your treatment — taken every day alongside other antivirals to keep the virus suppressed. PrEP is for people who are HIV-negat...
  • What exactly is the difference between using this for HIV treatment versus PrEP?
  • Please don't stop without talking to your doctor first. If you also have hepatitis B, stopping suddenly can trigger a serious and potentially dangerous flare-up of that infection....
  • Common things like nausea, headache, diarrhea, and trouble sleeping often improve in the first few weeks. The ones that need immediate attention are symptoms that could signal a ra...
📖 Read our full Emtricitabine and Tenofovir guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

We could not link this NDC to a current FDA Structured Product Label. An inactive-ingredient list is therefore not available from this source.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.457 $13.72 / 30 tablet
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2023 Feb 2024 Jan 2026 Mar 2026 $0.593 $0.457
▼ Down 17% over the last 7 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 42543-0719-04 Strides 30 tablets $0.451 AB Availability likely save 1%
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 64380-0719-04 Strides 30 tablets $0.451 AB Availability likely save 1%
Emtricitabine and tenofovir disoproxil fumarate 200; 300 mg/1; mgthis 60687-0719-25 American 1 tablet $0.457 AB Discontinued —
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 00093-7704-56 Teva 30 tablets $0.505 AB Availability likely +10%
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 00904-7172-07 Major 1 tablet $0.505 AB Availability likely +10%
Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg 16714-0534-01 NorthStar 30 tablets $0.505 AB Availability likely +10%
Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg 31722-0560-30 Camber 30 tablets $0.505 AB Availability likely +10%
Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg 33342-0106-07 Macleods 30 tablets $0.505 AB Availability likely +10%
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 42385-0953-30 Laurus 30 tablets $0.505 AB Availability likely +10%
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 65862-0354-30 Aurobindo 30 tablets $0.505 AB Availability likely +10%
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 69238-2095-03 Amneal 30 tablets $0.505 AB Availability likely +10%
Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg 70710-1367-03 Zydus 30 tablets $0.505 AB Availability likely +10%
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 82009-0109-30 QUALLENT 30 tablets $0.505 AB Availability likely +10%
Emtricitabine And Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 76282-0677-30 Exelan 30 tablets $0.569 — FDA listed +25%
Emtricitabine And Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 69097-0209-02 Cipla 30 tablets $0.593 — FDA listed +30%
Emtricitabine And Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 69097-0741-02 Cipla 30 tablets $0.593 — FDA listed +30%
Truvada 200 mg/1; 300 mg 61958-0701-01 Gilead 30 tablets $59.624 AB Availability likely +12942%
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 42291-0980-30 AvKARE 30 tablets — AB FDA listed —
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 50090-6494-01 A-S 30 tablets — AB FDA listed —
Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg 50090-7719-01 A-S 30 tablets — AB FDA listed —
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 51407-0112-30 Golden 30 tablets — AB FDA listed —
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 60219-2095-03 Amneal 30 tablets — AB FDA listed —
Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg 67296-2198-03 Redpharm 3 tablets — AB FDA listed —
Truvada 200 mg/1; 300 mg 68071-2112-03 NuCare 3 tablets — AB FDA listed —
Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg 68071-3695-03 NuCare 3 tablets — AB FDA listed —
Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg 68071-3831-03 NuCare 3 tablets — AB FDA listed —
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 68071-3986-03 NuCare 3 tablets — AB FDA listed —
Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg 70771-1709-03 Zydus 30 tablets — AB FDA listed —
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 71205-0776-07 Proficient 7 tablets — AB FDA listed —
Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 71335-2650-01 Bryant 30 tablets — AB FDA listed —
Emtricitabine And Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg 72189-0312-03 DirectRx 3 tablets — AB FDA listed —
Emtricitabine/TDF 300 mg/1; 200 mg 72189-0403-03 Direct_Rx 3 tablets — AB FDA listed —
Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg 82804-0086-03 Proficient 3 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

📍
2026
Currently FDA-listed
listed with the FDA
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
60687-0719-25 You're viewing this 30 BLISTER PACK in 1 CARTON (60687-719-25) / 1 TABLET, FILM COATED in 1 BLISTER PACK (60687-719-95) 2023-09-15 Discontinued by firm

🧭 About this NDC listing & data coverage

Finished prescription product No longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) — Not published for this NDC No structured label is linked to this listing in DailyMed/openFDA.
Package photos — Not published for this NDC The FDA label for this product carries no photos.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no full label on this page?
No structured FDA label (SPL) is currently linked to this NDC in DailyMed/openFDA. That can happen with older listings, certain OTC and repackaged products, and recently updated listings whose label has not yet propagated. The listing itself is still valid — this page shows everything the public feeds provide for this package.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 60687-719-25, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 60687-0719-25, written without dashes as 60687071925. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 60687-0719-25, the first segment (60687) is the labeler code FDA assigned to American Health Packaging; the middle segment (0719) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (25) identifies this exact package size and type. Together they name one specific package of one specific product.
Who lists this product with the FDA?
American Health Packaging is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
← 60687-0718-01 · American 60687-0720-21 · American →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.